DeutschNewstral
Article
Bbarrons.com on 2016-04-21 19:14
Sarepta Slammed by FDA, Stock Is Now Intriguing
Related news
- BSarepta Stock Is Spiking as FDA Reverses Course, Approving Drugbarrons.com
- BSarepta Got a Scathing FDA Rejection and Its Stock Is Fallingbarrons.com
- BSarepta Therapeutics Stock Sinks as FDA Questions Newest Muscular Dystrophy Drugbarrons.com
- MSarepta Therapeutics stock tanks after drug's FDA committee reviewmarketwatch.com
- MSarepta stock falls on FDA concerns about drugmarketwatch.com
- MSarepta stock drops on erroneous adverse event report to FDAmarketwatch.com
- MSarepta stock drops after Muscular Dystrophy study halted by FDAmarketwatch.com
After A 50% Fall Sarepta Therapeutics Stock Now Looks AttractiveForbes- MSarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drugmarketwatch.com
- BSarepta Stock Sinks on Stock Sale Announcement2 min readbarrons.com
- BSarepta Stock Plunges. FDA Pushes Back Decision Date on Gene Therapy. 2 min readbarrons.com
- MSarepta stock plummets 20% after FDA announces changes to investigational drug processmarketwatch.com
- MSarepta stock rises after FDA lifts clinical hold on gene therapy programmarketwatch.com
- How To Predict The Next Sarepta (FDA Approval Stock) And Win BigForbes
These Are Must-Watch Levels in Sarepta Stockprofitconfidential.com- Sarepta Stock Is Setting Up to Make a Substantial Moveprofitconfidential.com
- BSarepta Stock Is Falling on News It Could Cede Ground to Pfizerbarrons.com
- Sarepta Stock Under Bull Runprofitconfidential.com
- BSarepta Could Triple on Expedited FDA Approvalbarrons.com
- FSarepta shares surge 90% on FDA approvalft.com